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Abstract
IMPORTANCE Chinese women have the highest rate of lung cancer among female never-smokers
in the world, and the etiology is poorly understood.
OBJECTIVE To assess the association between metabolomics and lung cancer risk among never-
smoking women.
DESIGN, SETTING, AND PARTICIPANTS This nested case-control study included 275 never-
smoking female patients with lung cancer and 289 never-smoking cancer-free control participants
from the prospective Shanghai Women’s Health Study recruited from December 28, 1996, to May 23,
2000. Validated food frequency questionnaires were used for the collection of dietary information.
Metabolomic analysis was conducted from November 13, 2015, to January 6, 2016. Data analysis was
conducted from January 6, 2016, to November 29, 2018.
EXPOSURES Untargeted ultra-high-performance liquid chromatography–tandem mass
spectrometry and nuclear magnetic resonance metabolomic profiles were characterized using
prediagnosis urine samples. A total of 39 416 metabolites were measured.
MAIN OUTCOMES AND MEASURES Incident lung cancer.
RESULTS Among the 564 women, those who developed lung cancer (275 participants; median
[interquartile range] age, 61.0 [52-65] years) and those who did not develop lung cancer (289
participants; median [interquartile range] age, 62.0 [53-66] years) at follow-up (median
[interquartile range] follow-up, 10.9 [9.0-11.7] years) were similar in terms of their secondhand smoke
exposure, history of respiratory diseases, and body mass index. A peak metabolite, identified as
5-methyl-2-furoic acid, was significantly associated with lower lung cancer risk (odds ratio, 0.57 [95%
CI, 0.46-0.72]; P < .001; false discovery rate = 0.039). Furthermore, this peak was weakly correlated
with self-reported dietary soy intake (ρ = 0.21; P < .001). Increasing tertiles of this metabolite were
associated with lower lung cancer risk (in comparison with first tertile, odds ratio for second tertile,
0.52 [95% CI, 0.34-0.80]; and odds ratio for third tertile, 0.46 [95% CI, 0.30-0.70]), and the
association was consistent across different histological subtypes and follow-up times. Additionally,
metabolic pathway analysis found several systemic biological alterations that were associated with
lung cancer risk, including 1-carbon metabolism, nucleotide metabolism, oxidative stress, and
inflammation.
CONCLUSIONS AND RELEVANCE This prospective study of the untargeted urinary metabolome
and lung cancer among never-smoking women in China provides support for the hypothesis that
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Key Points
Question What is the association of
metabolomic biomarkers with lung
cancer in women who have
never smoked?
Findings In this case-control study of
275 never-smoking women with lung
cancer and 289 never-smoking cancer-
free women in China, the metabolite
5-methyl-2-furoic acid was correlated
with dietary soy consumption and
pathways including 1-carbon
metabolism, oxidative stress, nucleotide
metabolism, and inflammation and was
significantly associated with lower lung
cancer risk.
Meaning These findings suggest that
certain metabolites and pathways are
associated with lower lung cancer risk in
never-smoking women and biological
processes linked to air pollution may be
associated with higher lung cancer risk
in this population.
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(9):e1911970. doi:10.1001/jamanetworkopen.2019.11970 (Reprinted) September 20, 2019 1/12
Downloaded From: https://jamanetwork.com/ by a Murdoch University User  on 10/31/2019
Abstract (continued)
soy-based metabolites are associated with lower lung cancer risk in never-smoking women and
suggests that biological processes linked to air pollution may be associated with higher lung cancer
risk in this population.
JAMA Network Open. 2019;2(9):e1911970. doi:10.1001/jamanetworkopen.2019.11970
Introduction
Lung cancer is the leading cause of cancer mortality among men and women, accounting for 27% of
all cancer deaths worldwide and nearly 158 040 deaths in the United States in 2015.1 Although most
cases of lung cancer are caused by active tobacco smoking, approximately 25% occur in
never-smokers.2 Asian individuals (particularly Chinese women) have a higher rate of lung cancer
among never-smokers compared with individuals of European descent3; however, the etiology and
risk factors of this malignant neoplasm independent of smoking are poorly understood.4 Therefore, it
is imperative to understand the etiology of lung cancer and identify new biomarker targets or
metabolomic profiles as potential diagnostic and screening tools for lung cancer.
Altered tumor metabolism, a distinctive hallmark of many cancers, is required to acquire
sufficient nutrients to maintain deregulated and unlimited proliferation of the cancer cells.5 An
agnostic approach using untargeted metabolic profiling allows more comprehensive coverage of
downstream biological responses to environmental exposures, and can provide insight into
underlying molecular disease mechanisms.6 Metabolomic techniques have been used to identify
metabolites in various cancers.7-11 However, most of these metabolomic studies of cancer were
conducted using case-control study designs that compared the metabolite levels between
individuals diagnosed with cancer and healthy controls, which could be prone to reverse causation
bias. Targeted prospective studies have found some urinary metabolites to be associated with higher
lung cancer risk, including creatine riboside,12 N-acetylneuraminic acid,12 and 7-methylguanine.13
Both studies were conducted in populations of European descent and had small numbers of never-
smokers.
The Shanghai Women’s Health Study (SWHS) is a population-based prospective cohort of
73 363 female participants who were predominantly never-smokers. This study provides a unique
opportunity to prospectively evaluate the role of the metabolome in lung cancer development. To
our knowledge, this is the first prospective study to investigate prediagnostic metabolic biomarkers
and pathway alterations in urine samples using an untargeted approach among never-smoking
women, which may provide novel insights into the etiology and mechanisms associated with lung
cancer development in never-smokers.
Methods
Study Population
From December 28, 1996, to May 23, 2000, the SWHS recruited 73 363 Chinese women aged 40 to
70 years who were primarily never-smokers. In this nested case-control study, we performed
metabolomic profiling of all 275 female patients with incident lung cancer and 289 female healthy
controls who were individually matched on date of birth (±2 years) and date of spot urine sample
collection (±3 months). We followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline. Information on demographic characteristics, lifestyle,
diet, and medical history was obtained using a detailed survey administered in person at baseline.14
A comprehensive and validated food frequency questionnaire was used to assess dietary intake during
the year prior to the interview. Urine samples were collected into a sterilized cup containing 125 mg
of ascorbic acid to prevent oxidation of labile metabolites. After collection, the samples were kept at
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approximately 0°C to –4°C and were processed within 6 hours for long-term storage at −70°C.14 All
study participants provided written informed consent prior to participation, and the study protocols
were approved by institutional review boards of all participating institutes and the National Cancer
Institute.
Follow-up and Lung Cancer Identification
The participants were followed up with a combination of in-person surveys and periodic linkage to
cancer and vital statistics registries.14 Briefly, cohort members were followed up for diagnosis of
cancer by in-person surveys every 2 to 3 years and annual record linkage with databases from the
population-based Shanghai Cancer Registry, Shanghai Vital Statistics Registry, and Shanghai Resident
Registry. All possible cancer diagnoses were verified through home visits and a review of medical
records by a panel of oncologists. Lung cancer was defined as code 162 under the International
Classification of Diseases, Ninth Revision. All female patients with lung cancer were included as soon
as they were diagnosed after the baseline recruitment through December 31, 2009. Lung cancer
diagnosed before the recruitment was excluded. Information on histological subtypes of lung cancer
was extracted from medical records. Histological groups of lung cancer were classified according to
the morphology code of International Classification of Diseases for Oncology, Second Edition
(8140/3).15
Urinary Metabolomics
All urine samples (patient and pooled quality control samples) were analyzed in an untargeted
fashion by ultra-high-performance liquid chromatography–tandem mass spectrometry (UPLC-MS)
and 600-MHz hydrogen 1 nuclear magnetic resonance (NMR) spectroscopy at Imperial College
London, United Kingdom, acquired between November 13, 2015, and January 6, 2016. The spectral
data for the pooled quality control sample was collected after every 5 patient samples. The
measurements were carried out according to established protocols used for metabolic phenotyping
of biofluids.16,17 For the UPLC-MS measurements, metabolic profiling was performed on an ACQUITY
UPLC System (Waters Corp) coupled to a Xevo Triple Quadrupole Mass Spectrometer (Waters Corp)
following a standard set of protocols.18 Mass spectrometry was performed using electrospray in both
positive and negative ionization (electrospray ionization [ESI]+ and ESI−) modes under conditions
described previously.19 This UPLC-MS method allows for a high-resolution, accurate, and
simultaneous detection of thousands of peaks that correspond to individual ions with a unique mass
to charge (m/z) ratio and retention time.20
Each UPLC-MS data set was preprocessed using Progenisis (Non Linear Dynamics) to convert
the 3-dimensional UPLC-MS raw data into time-aligned detected features of retention time, m/z
ratio, and intensity (peak area). The ion intensities for each peak detected were then normalized,
within each sample, to the median peak intensity in that sample. The metabolic profiling data were
preprocessed using the freely available XCMS software (Scripps Research Institute) to detect and
identify peaks, align retention time, and perform normalization of the raw mass spectrometry data
before subsequent statistical analysis.19,21 The resulting features were filtered to remove features
with a coefficient of variation greater than 30% across the quality control samples. The NMR data
were imported into MATLAB R2012b (Natick) using the Metaspectra program script, using a
resolution of 0.00055. The data were then aligned using recursive segmentwise peak alignment22
and normalized by probabilistic quotient to account for and exclude systematic sources of bias within
samples not due to biological processes or the environment. Statistical recoupling of variables23 was
then used for peak detection. The resulting tables were imported to SIMCA-P+ software version
13.0.2 (Umetrics) to perform multivariate statistical analysis. In total, there were 20 555 UPLC-MS
peaks in positive mode, 18 475 in negative mode, and 386 NMR peaks.
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Statistical Analysis
A small constant (1 × 10−9) was added to all metabolite levels, which were then natural
log–transformed to approximate normal distributions and subsequently analyzed as both continuous
and categorical variables (based on tertiles among controls). Principal component analysis, partial
least-squares–discriminant analysis, and orthogonal projection on latent structures–discriminant
analysis (OPLS-DA) were performed on all data to check for batch effects and clustering of samples.
The characteristics of patients with lung cancer and control individuals were compared using
the Wilcoxon rank sum test for continuous variables and Fisher exact test for categorical variables.
Analyses were restricted to lifetime never-smokers (275 female patients with lung cancer and 289
controls). Separate unconditional logistic regression models were used to estimate the odds ratios
(ORs) and 95% confidence intervals for the associations between each metabolite and lung cancer
risk. Tests of trend were calculated by treating the level of each metabolite as a continuous variable.
We also stratified the analysis by follow-up time (<9 years [the median duration of follow-up] or 9
years) and major lung cancer subtypes (adenocarcinoma, nonadenocarcinoma). Because dietary
intake has previously been reported to be associated with altered metabolites in urine samples, using
a multivariable linear regression model, we evaluated the associations between the most significant
metabolite and prediagnosis dietary factors among female patients with lung cancer and controls. In
addition, because soy food intake has been previously found to be associated with risk of lung cancer
in the SWHS,24 we further looked at grouped soy intake, which included 11 soy food items that are
commonly consumed in Shanghai, including soy milk, tofu, fried tofu, dried or pressed tofu, fresh
green soy beans, dry soy beans, soy sprouts, and other soy products. In addition, mediation analysis
was used to estimate the proportion of the mediated effect via the significant metabolites on the
association between soy consumption and lung cancer risk.25 Missing data were excluded from all
analyses. All models were adjusted for age (continuous), body mass index, history of respiratory
diseases (categorical; ever or never) and environmental tobacco smoke (categorical; ever or never).
Correlations among significant metabolites, as well as between significant metabolites and 17 dietary
factors, were evaluated using Spearman correlation coefficients.
All statistical analyses were conducted using R statistical software version 3.2.2 (R Project for
Statistical Computing) and SAS statistical software version 4.3 (SAS Institute). All tests with a false
discovery rate (FDR) of less than 0.10 were considered statistically significant. All P values were
reported based on 2-sided tests and P < .05 was considered statistically significant. We calculated
FDRs using the Benjamini-Hochberg method to account for multiple comparisons.26
Metabolite Identification
The metabolic phenotypes of female patients with lung cancer and controls were further evaluated
using pathway enrichment to identify biological processes associated with lung cancer diagnosis. In
this analysis, we tested all metabolic features for their association with lung cancer diagnosis.
Pathway enrichment analysis was completed using all metabolic features with P < .05. This threshold
minimizes type II error (false-negatives) at the increased risk of type I error (false-positives). The
pathway enrichment approach uses a random sampling framework to identify a null distribution of
metabolites across a metabolic network; comparison of the null distribution with annotated
metabolites from signals with P < .05 removes false-positives, which would be randomly distributed
across the metabolic map, and allows isolation of biological effects. The pathway enrichment was
completed separately for positive- and negative-mode data using the mummichog analysis
approach27; pathways with P < .05 were selected for further characterization. Metabolites were
identified and annotated based on accurate mass (for UPLC-MS) and by using in-house and available
online databases such as the Human Metabolome Database and METLIN.
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Results
Among the 564 women, those who developed lung cancer (275 participants; median [interquartile
range {IQR}] age, 61.0 [52-65] years) and those who did not develop lung cancer (289 participants;
median [IQR] age, 62.0 [53-66] years) at follow-up were similar in terms of secondhand smoke
exposure, history of respiratory diseases, and body mass index (Table 1). The median (IQR) time from
the baseline questionnaire to lung cancer diagnosis was 9.26 (6.69-11.05) years.
Using an FDR cutoff of 10% to adjust for multiple comparisons, 3 urinary metabolites by
UPLC-MS were significantly associated with lower lung cancer risk (Table 2). The statistically
significant metabolites were pos_2.61_127.0382m/z (OR, 0.57 [95% CI, 0.46-0.72]; P < .001;
FDR = 0.039), neg_2.60_369.0408m/z (OR, 0.97 [95% CI, 0.96-0.98]; P < .001; FDR = 0.039), and
pos_2.61_184.0325n (OR, 0.55 [95% CI, 0.43-0.71]; P < .001; FDR = 0.065). The 3 significant
metabolites were highly correlated with each other (Spearman correlations ranged from 0.67-0.89)
(eTable 1 in the Supplement). In addition, results were comparable when stratified by follow-up time
(<9 years of follow-up and 9 years of follow-up) after urine sample collection (Table 2). Similar
results were also obtained after excluding 4 women who were diagnosed within 2 years after the
baseline interview (data not shown). Furthermore, similar associations were observed among
patients with lung adenocarcinoma (135 patients [49.1%]) and those with unclassified lung cancer
(104 patients [37.8%]) (eTable 2 and eTable 3 in the Supplement). None of the NMR features were
significantly associated with lung cancer risk (data not shown).
Table 1. Characteristics of the Nested Case-Control Study of Never-Smoking Women





(n = 289) P Valuea
Environmental tobacco smoke, No. (%)
Never 70 (25.5) 71 (24.6)
.86Ever 187 (68) 200 (69.2)
Missing 18 (6.5) 18 (6.2)
History of respiratory diseases, No. (%)
Yes 28 (10.2) 22 (7.6)
.36
No 247 (89.8) 267 (92.4)
Age at baseline, median (IQR), y 61.0 (52-65) 62.0 (53-66) .42
BMI, median (IQR) 24.3 (22.4-26.6) 24.3 (22.0-26.9) .84
Time to diagnosis, median (IQR), y 9.26 (6.69-11.1) NA NA
Histological subtypes, No. (%)
Adenocarcinoma 135 (49.1) NA
NA
Squamous cell carcinoma 9 (3.3) NA
Other histology subtypes 19 (6.9) NA
Unclassified 104 (37.8) NA
No ICD-O-2 code 8 (2.9) NA
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); ICD-O-2, International Classification of
Diseases for Oncology, Second Revision; IQR,
interquartile range; NA, not applicable.
a P values were obtained from Wilcoxon signed-rank
test for continuous variables and Fisher exact test for
categorical variables.
Table 2. Associations Between Urinary Metabolites and Lung Cancer Risk, Stratified by Follow-up Time
Metabolitea OR (95% CI)b P Value FDR
Follow-up
<9 yc ≥9 yd
OR (95% CI)b P Value OR (95% CI)b P Value
pos_2.61_127.0382m/z 0.57 (0.46-0.72) <.001 0.039 0.51 (0.38-0.70) <.001 0.62 (0.48-0.81) <.001
neg_2.60_369.0408m/z 0.97 (0.96-0.98) <.001 0.039 0.97 (0.95-0.98) <.001 0.97 (0.96-0.99) <.001
pos_2.61_184.0325n 0.55 (0.43-0.71) <.001 0.065 0.49 (0.35-0.69) <.001 0.60 (0.44-0.82) .001
Abbreviations: FDR, false discovery rate; OR, odds ratio.
a Metabolites were natural log–transformed.
b All models were adjusted for age, body mass index, history of respiratory diseases, and
secondhand smoke exposure.
c Sample sizes were 131 with lung cancer and 289 without lung cancer.
d Sample sizes were 144 with lung cancer and 289 without lung cancer.
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One of the significant metabolites (pos_2.61_127.0382m/z) was identified as 5-methyl-2-furoic
acid based on its fragmentation pattern by tandem mass spectrometry (eTable 4 in the Supplement).
There was a significant monotonic dose-response association between 5-methyl-2-furoic acid and
lung cancer risk when analyzed as tertiles (Table 3). Increasing tertiles of the metabolite level were
significantly associated with lower lung cancer risk (in comparison with first tertile, OR for second
tertile, 0.52 [95% CI, 0.34-0.80]; and OR for third tertile, 0.46 [95% CI, 0.30-0.70]; P for
trend < .001). Similar trends were observed for the 2 other significant metabolites (eTable 5 in the
Supplement).
Because dietary intake has been previously reported to be associated with altered metabolites
in urine samples, we also assessed the correlation of each available dietary factor with the level of
5-methyl-2-furoic acid. Consumption of soy food, including soy milk, tofu, fried tofu, dried or pressed
tofu, fresh green soy beans, dry soy beans, soy sprouts, and other soy products, in the past year had
a weak positive correlation with levels of 5-methyl-2-furoic acid among controls (ρ = 0.21; P < .001)
(eTable 6 in the Supplement). Using mediation analysis, we found that 25% of the association
between soy consumption and higher lung cancer risk was significantly mediated via 5-
methyl-2-furoic acid.
Regression analysis included 152 positive-mode and 186 negative-mode features associated
with lung cancer risk at P < .05; only 4 features were present with Bonferroni correction less than .05.
Pathway enrichment identified 40 metabolic pathways associated with lung cancer risk at P < .05,
including 8 pathways meeting a Bonferroni-corrected P < .05 (Figure). Eight were detected in both
modes and included amino acid metabolism, nucleotide metabolism, nitrogen catabolism, and B
vitamin pathways. Metabolic alterations associated with lung cancer risk suggest systemic changes
to key biological processes, including 1-carbon metabolism (vitamin B9 [folate] metabolism; glycine,
serine, alanine, and threonine metabolism), oxidative stress pathways (ascorbate [vitamin C] and
aldarate metabolism, methionine and cysteine metabolism, glutamate metabolism), nucleotide
metabolism (purine metabolism), and inflammation (leukotriene metabolism).
Discussion
To our knowledge, this is the first large-scale prospective study of untargeted de novo metabolomics
in association with lung cancer among never-smoking Chinese women. We found 3 metabolites
associated with a reduction of lung cancer risk after accounting for multiple comparisons. These
metabolites were highly correlated with each other and may represent the same chemical family
and/or source. One of these metabolites (pos_2.61_127.0382m/z) was identified as 5-methyl-2-furoic
acid, which belongs to the family of furoic acid derivatives. It was weakly correlated with dietary soy








Cancer, No. OR (95% CI)a P Value P for Trend
First tertile, median = 10.5 139 96 1 [Reference] NA
<.001Second tertile, median = 11.3 71 95 0.52 (0.34-0.80) .003
Third tertile, median = 12.1 64 96 0.46 (0.30-0.70) <.001
<9-y follow-up
First tertile, median = 10.5 69 96 1 [Reference] NA
<.001Second tertile, median = 11.3 34 96 0.51 (0.30-0.86) .01
Third tertile, median = 12.1 27 96 0.36 (0.20-0.63) <.001
≥9-y follow-up
First tertile, median = 10.4 70 96 1 [Reference] NA
.02Second tertile, median = 11.2 37 96 0.53 (0.32-0.89) .02
Third tertile, median = 12.1 37 96 0.56 (0.34-0.93) .03
Abbreviations: OR, odds ratio; NA, not applicable.
a All models were adjusted for age, body mass index,
history of respiratory diseases, and secondhand
smoke exposure.
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intake in our study population, suggesting that this metabolite may be partially derived from
soy-related dietary products. Metabolic alterations identified in the pathway enrichment analysis
suggest lung cancer risk is associated with an increased oxidative state and depletion of systemic
antioxidant pathways.
Furan fatty acids are related compounds that occur naturally in foods such as soybean oil28 and
have also been shown to have anti-inflammatory and antioxidant properties in vivo.29 Methylated
and furan-containing fatty acids have also been demonstrated to protect against reactive oxygen
species–mediated damage in vivo by acting as scavengers of reactive oxygen species.30 Interestingly,
we found higher levels of the furoic acid metabolite in urine to be associated with a lower risk of lung
cancer. Another furoic acid derivative, 5-tetradecyl-oxy-2-furoic acid (TOFA), has been reported to
reduce fatty acid synthesis by inhibiting acetyl coenzyme A carboxylase-α (ACCA), thereby increasing
apoptosis rates and eradicating prostate cancer cells via the mitochondrial pathway.31 One study32
identified TOFA as a potent inhibitor of stearoyl coenzyme A desaturase 1 (SCD1), which is an enzyme
in the fatty-acid synthesis pathway that depletes monounsaturated fatty acids and therefore restricts
cancer cell proliferation. Furoic acid is derived from furans, which are commonly used as food
additives, and preservatives, which are usually present in high levels in heat-treated foods such as
soy sauce, baked beans, and brewed coffee.33
Dietary soy intake was previously shown to be associated with a 37% lower risk of lung cancer
among a population of Chinese women in Shanghai, comparing the highest quintile with the lowest
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Pathway enrichment was identified using the
mummichog analysis approach and identified 40
metabolic pathways associated with lung cancer risk,
including 8 pathways meeting a Bonferroni-corrected
P < .05. Circle size is proportional to the number of
metabolites associated with lung cancer diagnosis
from each pathway. The placement of circles along the
x-axis indicate the statistical significance of each
pathway. The dotted line indicates the significance
level using Bonferroni P = .05. CoA indicates
coenzyme A.
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quintile.24 This is consistent with our findings in the same population of a significant protective
association between 5-methyl furan-2-carboxylic acid and lung cancer risk, and a significant weak
correlation between this metabolite and dietary soy intake. Soy foods contain high concentrations of
isoflavones, a type of phytoestrogen, which possess antiestrogenic and antioxidative effects.34 It has
been hypothesized that the bioactive compounds of dietary soy may contain antioxidant and anti-
inflammatory properties that inhibit tumor growth and invasion and induce apoptosis.35-37
Evaluating pathway (rather than individual metabolite) changes associated with disease risk
provides a systems biology approach that can be used to understand the metabolic effects of lung
cancer pathobiology. In the present study, we identified alterations in pathways that suggest
dysregulation of 1-carbon metabolism and related pathways, including folate, methionine and
cysteine metabolism, purine metabolism, and glycine, serine, alanine, and threonine metabolism.
One-carbon metabolism is critical in intermediary metabolism and supports multiple biological
processes, including nucleotide metabolism, amino acid metabolism, and homeostasis (methionine
and cysteine, serine, and glycine).38
Our study suggests that metabolic alterations in oxidative stress and inflammatory pathways,
which could arise from multiple exogenous and endogenous exposures and biological processes, are
associated with lung cancer risk in never-smoking women in China. It is, however, intriguing that
these same pathways have also been linked to exposure to environmental pollutants that are
suspected to be associated with higher lung cancer disease risk,39,40 including traffic-related air
pollution.41-44 Taken together, the overlap in oxidative stress and inflammation metabolites suggest
environmental exposures and lung cancer risk in this population may share similarities in metabolic
alterations and provide an indirect link between the two. Additional studies are needed to evaluate
these possible associations.
One major strength of this study is that the metabolites were measured in never-smoking
women, thereby eliminating the possibility of confounding by active smoking, which has occurred in
other studies. Other strengths of this study include the prospective design, in which the collection
of urinary metabolomic biomarkers preceded lung cancer diagnosis, which provides exposure-
outcome temporality, and the untargeted measurement of metabolites, which provides increased
opportunities for making novel discoveries.
Limitations
There were limitations to this study. One is that a notable proportion of the cohort with lung cancer
(40.7%) had an unclassified histological subtype. However, analysis of unclassified lung cancer
yielded results that were similar to analysis of all lung cancer and of lung adenocarcinoma only. The
source of the dietary data was a food frequency questionnaire designed to assess dietary patterns in
the past year when the baseline interview was conducted. The exact question asked in the
questionnaire was, “Would you please tell me if you ate those foods and how much you ate in general
over the past year?” Given that most metabolites have relatively short half-lives, the weak correlation
between 5-methyl-2-furoic acid and dietary soy intake may have been stronger if we had
questionnaire or diary data for the last few days before urine was collected. In addition, the urine
samples were only collected once and we were unable to assess the temporal trends of metabolites
over time.
Conclusions
This nested case-control study found that a urinary metabolite, 5-methyl-2-furoic acid, was
associated with decreased risk of lung cancer in a prospective cohort of never-smoking women. The
identified significant metabolite (5-methyl-2-furoic acid) was weakly correlated with self-reported
usual dietary intake of soy. Furthermore, our finding is consistent with recent epidemiological
evidence showing that higher dietary soy consumption may be associated with decreased lung
cancer risk among never-smokers, strengthening the biological relevance of the identified
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metabolite. In addition, metabolic pathways associated with lung cancer risk suggest systemic
biological alterations were present, and a number of pathways identified in the present study have
been linked to results of previous metabolomic studies of populations exposed to air pollution, a
suspected risk factor for lung cancer. Additional studies are warranted to replicate and further
characterize the associations reported in our study, which provide additional clues about the
exposures and biological processes that may contribute to the risk of lung cancer in never-smoking
populations in Asia.
ARTICLE INFORMATION
Accepted for Publication: August 4, 2019.
Published: September 20, 2019. doi:10.1001/jamanetworkopen.2019.11970
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Seow WJ et al.
JAMA Network Open.
Corresponding Author: Wei Jie Seow, ScD, Saw Swee Hock School of Public Health, National University of
Singapore, 12 Science Drive 2, 09-01H, Singapore 117549 (ephswj@nus.edu.sg).
Author Affiliations: Saw Swee Hock School of Public Health, National University of Singapore and National
University Health System, Singapore (Seow); Department of Medicine, Yong Loo Lin School of Medicine, National
University of Singapore and National University Health System, Singapore (Seow); Division of Cancer
Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland (Seow, Hu,
Moore, Bassig, Wong, Zhang, Ji, Rothman, Lan); Division of Epidemiology, Department of Medicine, Vanderbilt
University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee (Shu, Cai, Zheng);
Biomolecular Medicine, Division of Computational and Systems Medicine, Medical Research Council–National
Institute for Health Research National Phenome Centre, Imperial College London, United Kingdom (Nicholson,
Holmes, Boulangé, Kaluarachchi, Wijeyesekera, Elliott); Medical Research Council–PHE Centre for Environment
and Health, Department of Surgery and Cancer, Imperial College London, United Kingdom (Nicholson, Holmes,
Boulangé, Kaluarachchi, Wijeyesekera, Elliott); Health Futures Institute, Murdoch University, Murdoch, Western
Australia, Australia (Nicholson, Holmes); Department of Environmental Medicine and Public Health, Icahn School
of Medicine at Mount Sinai, New York, New York (Walker); Department of Epidemiology, Shanghai Cancer Institute,
Shanghai, China (Gao, Xiang); State Key Laboratory of Oncogene and Related Genes, Renji Hospital, Shanghai
Jiaotong University School of Medicine, Shanghai, China (Xiang); MRC-PHE Centre for Environment and Health,
School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, United Kingdom
(Elliott); National Institute for Health Research, Imperial College Biomedical Research Centre, London, United
Kingdom (Elliott); Health Data Research UK London at Imperial College London, United Kingdom (Elliott).
Author Contributions: Drs Seow and Lan had full access to all of the data in the study and take responsibility for
the integrity of the data and the accuracy of the data analysis. Drs Seow, Shu, Nicholson, Holmes, and Walker
contributed equally to the study.
Concept and design: Seow, Shu, Elliott, Rothman, Lan.
Acquisition, analysis, or interpretation of data: Seow, Nicholson, Holmes, Walker, Hu, Cai, Gao, Xiang, Moore,
Bassig, Wong, Zhang, Ji, Boulangé, Kaluarachchi, Wijeyesekera, Zheng, Rothman, Lan.
Drafting of the manuscript: Seow, Walker, Lan.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Seow, Holmes, Walker, Moore, Wong, Boulangé, Kaluarachchi, Lan.
Obtained funding: Shu, Rothman, Lan.
Administrative, technical, or material support: Shu, Hu, Gao, Xiang, Wong, Ji, Boulangé, Kaluarachchi,
Wijeyesekera.
Supervision: Nicholson, Gao, Elliott, Rothman, Lan.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by intramural funds from the National Cancer Institute and the
National University of Singapore Start-up Grant. The Shanghai Women’s Health Study is supported by the US
National Institutes of Health/National Cancer Institute (grant UM1 CA182910).
JAMA Network Open | Oncology Untargeted Urinary Metabolomics and Lung Cancer Risk Among Never-Smoking Women
JAMA Network Open. 2019;2(9):e1911970. doi:10.1001/jamanetworkopen.2019.11970 (Reprinted) September 20, 2019 9/12
Downloaded From: https://jamanetwork.com/ by a Murdoch University User  on 10/31/2019
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and
decision to submit the manuscript for publication.
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. doi:10.3322/caac.21254
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;7(10):
778-790. doi:10.1038/nrc2190
3. Epplein M, Schwartz SM, Potter JD, Weiss NS. Smoking-adjusted lung cancer incidence among Asian-Americans
(United States). Cancer Causes Control. 2005;16(9):1085-1090. doi:10.1007/s10552-005-0330-6
4. Thun MJ, Hannan LM, Adams-Campbell LL, et al. Lung cancer occurrence in never-smokers: an analysis of 13
cohorts and 22 cancer registry studies. PLoS Med. 2008;5(9):e185. doi:10.1371/journal.pmed.0050185
5. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47. doi:
10.1016/j.cmet.2015.12.006
6. Vrijheid M. The exposome: a new paradigm to study the impact of environment on health. Thorax. 2014;69(9):
876-878. doi:10.1136/thoraxjnl-2013-204949
7. Hori S, Nishiumi S, Kobayashi K, et al. A metabolomic approach to lung cancer. Lung Cancer. 2011;74(2):
284-292. doi:10.1016/j.lungcan.2011.02.008
8. Wittmann BM, Stirdivant SM, Mitchell MW, et al. Bladder cancer biomarker discovery using global metabolomic
profiling of urine. PLoS One. 2014;9(12):e115870. doi:10.1371/journal.pone.0115870
9. Yu L, Jiang C, Huang S, Gong X, Wang S, Shen P. Analysis of urinary metabolites for breast cancer patients
receiving chemotherapy by CE-MS coupled with on-line concentration. Clin Biochem. 2013;46(12):1065-1073. doi:
10.1016/j.clinbiochem.2013.05.049
10. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH. Urine metabolomic analysis identifies potential
biomarkers and pathogenic pathways in kidney cancer. OMICS. 2011;15(5):293-303. doi:10.1089/omi.2010.0094
11. Playdon MC, Ziegler RG, Sampson JN, et al. Nutritional metabolomics and breast cancer risk in a prospective
study. Am J Clin Nutr. 2017;106(2):637-649. doi:10.3945/ajcn.116.150912
12. Haznadar M, Cai Q, Krausz KW, et al. Urinary metabolite risk biomarkers of lung cancer: a prospective cohort
study. Cancer Epidemiol Biomarkers Prev. 2016;25(6):978-986. doi:10.1158/1055-9965.EPI-15-1191
13. Loft S, Svoboda P, Kasai H, et al. Prospective study of urinary excretion of 7-methylguanine and the risk of lung
cancer: effect modification by mu class glutathione-S-transferases. Int J Cancer. 2007;121(7):1579-1584. doi:10.
1002/ijc.22863
14. Zheng W, Chow WH, Yang G, et al. The Shanghai Women’s Health Study: rationale, study design, and baseline
characteristics. Am J Epidemiol. 2005;162(11):1123-1131. doi:10.1093/aje/kwi322
15. Wu QJ, Xiang YB, Yang G, et al. Vitamin E intake and the lung cancer risk among female nonsmokers: a report
from the Shanghai Women’s Health Study. Int J Cancer. 2015;136(3):610-617.
16. Dona AC, Jiménez B, Schäfer H, et al. Precision high-throughput proton NMR spectroscopy of human urine,
serum, and plasma for large-scale metabolic phenotyping. Anal Chem. 2014;86(19):9887-9894. doi:10.1021/
ac5025039
17. Lewis MR, Pearce JT, Spagou K, et al. Development and application of ultra-performance liquid
chromatography-TOF MS for precision large scale urinary metabolic phenotyping. Anal Chem. 2016;88(18):
9004-9013. doi:10.1021/acs.analchem.6b01481
18. Wijeyesekera A, Clarke PA, Bictash M, et al. Quantitative UPLC-MS/MS analysis of the gut microbial
co-metabolites phenylacetylglutamine, 4-cresyl sulphate and hippurate in human urine: INTERMAP Study. Anal
Methods. 2012;4(1):65-72. doi:10.1039/C1AY05427A
19. Swann JR, Spagou K, Lewis M, et al. Microbial-mammalian cometabolites dominate the age-associated urinary
metabolic phenotype in Taiwanese and American populations. J Proteome Res. 2013;12(7):3166-3180. doi:10.
1021/pr4000152
20. Broeckling CD, Heuberger AL, Prenni JE. Large scale non-targeted metabolomic profiling of serum by ultra
performance liquid chromatography-mass spectrometry (UPLC-MS). J Vis Exp. 2013;(73):e50242.
21. Want EJ, Masson P, Michopoulos F, et al. Global metabolic profiling of animal and human tissues via UPLC-MS.
Nat Protoc. 2013;8(1):17-32. doi:10.1038/nprot.2012.135
22. Veselkov KA, Lindon JC, Ebbels TM, et al. Recursive segment-wise peak alignment of biological (1)h NMR
spectra for improved metabolic biomarker recovery. Anal Chem. 2009;81(1):56-66. doi:10.1021/ac8011544
JAMA Network Open | Oncology Untargeted Urinary Metabolomics and Lung Cancer Risk Among Never-Smoking Women
JAMA Network Open. 2019;2(9):e1911970. doi:10.1001/jamanetworkopen.2019.11970 (Reprinted) September 20, 2019 10/12
Downloaded From: https://jamanetwork.com/ by a Murdoch University User  on 10/31/2019
23. Blaise BJ, Shintu L, Elena B, Emsley L, Dumas ME, Toulhoat P. Statistical recoupling prior to significance testing
in nuclear magnetic resonance based metabonomics. Anal Chem. 2009;81(15):6242-6251. doi:10.1021/
ac9007754
24. Yang G, Shu XO, Chow WH, et al. Soy food intake and risk of lung cancer: evidence from the Shanghai Women’s
Health Study and a meta-analysis. Am J Epidemiol. 2012;176(10):846-855. doi:10.1093/aje/kws168
25. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R package for causal mediation analysis. J Stat
Softw. 2014;59(5). doi:10.18637/jss.v059.i05
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate—a practical and powerful approach to multiple
testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300.
27. Li S, Park Y, Duraisingham S, et al. Predicting network activity from high throughput metabolomics. PLoS
Comput Biol. 2013;9(7):e1003123. doi:10.1371/journal.pcbi.1003123
28. Wendlinger C, Vetter W. High concentrations of furan fatty acids in organic butter samples from the German
market. J Agric Food Chem. 2014;62(34):8740-8744. doi:10.1021/jf502975b
29. Wakimoto T, Kondo H, Nii H, et al. Furan fatty acid as an anti-inflammatory component from the green-lipped
mussel Perna canaliculus. Proc Natl Acad Sci U S A. 2011;108(42):17533-17537. doi:10.1073/pnas.1110577108
30. Lemke RA, Peterson AC, Ziegelhoffer EC, et al. Synthesis and scavenging role of furan fatty acids. Proc Natl
Acad Sci U S A. 2014;111(33):E3450-E3457. doi:10.1073/pnas.1405520111
31. Guseva NV, Rokhlin OW, Glover RA, Cohen MB. TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid
synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53
status. Cancer Biol Ther. 2011;12(1):80-85. doi:10.4161/cbt.12.1.15721
32. Mason P, Liang B, Li L, et al. SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty
acids. PLoS One. 2012;7(3):e33823. doi:10.1371/journal.pone.0033823
33. Morehouse KM, Nyman PJ, McNeal TP, Dinovi MJ, Perfetti GA. Survey of furan in heat processed foods by
headspace gas chromatography/mass spectrometry and estimated adult exposure. Food Addit Contam Part A
Chem Anal Control Expo Risk Assess. 2008;25(3):259-264. doi:10.1080/02652030701552949
34. Franke AA, Custer LJ, Wang W, Shi CY. HPLC analysis of isoflavonoids and other phenolic agents from foods
and from human fluids. Proc Soc Exp Biol Med. 1998;217(3):263-273. doi:10.3181/00379727-217-44231
35. Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O. Effect of soy isoflavone supplementation on markers of
oxidative stress in men and women. Cancer Lett. 2001;172(1):1-6. doi:10.1016/S0304-3835(01)00627-9
36. Yu J, Bi X, Yu B, Chen D. Isoflavones: anti-inflammatory benefit and possible caveats. Nutrients. 2016;8
(6):E361. doi:10.3390/nu8060361
37. Yoon GA, Park S. Antioxidant action of soy isoflavones on oxidative stress and antioxidant enzyme activities in
exercised rats. Nutr Res Pract. 2014;8(6):618-624. doi:10.4162/nrp.2014.8.6.618
38. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab. 2017;25(1):27-42. doi:
10.1016/j.cmet.2016.08.009
39. Ladva CN, Golan R, Liang D, et al. Particulate metal exposures induce plasma metabolome changes in a
commuter panel study. PLoS One. 2018;13(9):e0203468. doi:10.1371/journal.pone.0203468
40. Wang Z, Zheng Y, Zhao B, et al. Human metabolic responses to chronic environmental polycyclic aromatic
hydrocarbon exposure by a metabolomic approach. J Proteome Res. 2015;14(6):2583-2593. doi:10.1021/acs.
jproteome.5b00134
41. Donaldson K, Stone V, Seaton A, MacNee W. Ambient particle inhalation and the cardiovascular system:
potential mechanisms. Environ Health Perspect. 2001;109(suppl 4):523-527.
42. Bates JT, Weber RJ, Abrams J, et al. Reactive oxygen species generation linked to sources of atmospheric
particulate matter and cardiorespiratory effects. Environ Sci Technol. 2015;49(22):13605-13612. doi:10.1021/acs.
est.5b02967
43. Chuang KJ, Chan CC, Su TC, Lee CT, Tang CS. The effect of urban air pollution on inflammation, oxidative
stress, coagulation, and autonomic dysfunction in young adults. Am J Respir Crit Care Med. 2007;176(4):370-376.
doi:10.1164/rccm.200611-1627OC
44. Sørensen M, Daneshvar B, Hansen M, et al. Personal PM2.5 exposure and markers of oxidative stress in blood.
Environ Health Perspect. 2003;111(2):161-166. doi:10.1289/ehp.111-1241344
SUPPLEMENT.
eTable 1. Spearman Correlations Between Significant Metabolites (<10% FDR) in Controls Only, Cases Only and
Overall Study Population
JAMA Network Open | Oncology Untargeted Urinary Metabolomics and Lung Cancer Risk Among Never-Smoking Women
JAMA Network Open. 2019;2(9):e1911970. doi:10.1001/jamanetworkopen.2019.11970 (Reprinted) September 20, 2019 11/12
Downloaded From: https://jamanetwork.com/ by a Murdoch University User  on 10/31/2019
eTable 2. Associations Between Urinary Metabolites and Lung Cancer Risk, Stratified by Lung Cancer Subtypes
eTable 3. Associations Between the Most Significant Metabolite (5-Methyl-2-Furoic Acid) and Lung Cancer in
Tertiles, Stratified by Lung Cancer Subtypes
eTable 4. Identification of the Top Three Metabolites
eTable 5. Associations Between neg_2.60_369.0408mz, pos_2.61_184.0325n and Lung Cancer, by Tertiles
eTable 6. Univariate Linear Regression and Correlation Between the Most Significant Metabolite (5-Methyl-2-
Furoic Acid) and Diet Variables Among Controls
JAMA Network Open | Oncology Untargeted Urinary Metabolomics and Lung Cancer Risk Among Never-Smoking Women
JAMA Network Open. 2019;2(9):e1911970. doi:10.1001/jamanetworkopen.2019.11970 (Reprinted) September 20, 2019 12/12
Downloaded From: https://jamanetwork.com/ by a Murdoch University User  on 10/31/2019
